Summary:
CONCLUSIONS: Survival outcomes for LS-SCLC remain poor despite curative-intent multimodality treatment. Immunotherapy represents a promising advance but a high proportion of patients in the real-world receive treatment that was not represented in the ADRIATIC trial. Future work evaluating the outcomes of patients treated with immunotherapy is critical to assess its real-world impact.
Link:
https://pubmed.ncbi.nlm.nih.gov/41273996/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=12QQbiNmM99eUQGIX1JjHIKcROC1Vzv4sOS-2S_LNI19uG_Yrk&fc=20220129225649&ff=20251123043554&v=2.18.0.post22+67771e2
From feeds:
📚BioDBS Bibliography »
database[Title]
Tags:
Authors:
William J Phillips, Luna Jia Zhan, Deepro Chowdhury, Jeniszka Gill, Alexander Sun, Rebekah Rittberg, Victor Cohen, Amanda J W Gibson, Michael Yan, Daniel Liwski, Saritha Surapaneni, Marie Frederique D'Amours, Fabian P S Yu, YongJin Kim, Rana A Qadeer, David E Dawe, Jason Agulnik, Vishal Navani, Andrea S Fung, Stephanie Snow, Sara Kuruvilla, Cheryl Ho, Benjamin H Lok, Geoffrey Liu, Paul Wheatley-Price, Sara Moore
Date tagged:
11/23/2025, 04:35
Date published:
11/22/2025, 06:00